Merck + Co., Inc.

Guadalupe A Limjuco

Dennis J Carlo

Yashwant D Karkhanis

Jack A Schmidt

Patricia M Cameron

Human interleukin-1 (IL-1) charged species (pI 6.8, 6.0, 5.4 and 5.2) are separated and purified by a rapid and efficient two or three stage chromatographic process. Interleukin-1 species present in concentrated culture fluid from stimulated human mononuclear cells are separated and partially purified by anion exchange high performance liquid chromatography. The pI 5.4 and 5.2 species in addition are partially purified by HPLC gel filtration chromatography. Each of the individual IL-1 species are then finally purified by reverse phase high performance liquid chromatography. This process results in homogenously pure pI 6.8, pI 5.4 and pI 5.2 species while the pI 6.0 species is isolated in a substantially pure form.

Purification of human interleukin-1 species

A vaccine against E. coli caused diarrhea is prepared from an isolate of the homogeneous heat-labile enterotoxin of human strain MB3353 of Escherichia coli, ATCC 31361, or of the porcine strain MB3708, ATCC 31362. The toxin, which is a protein, is a low molecular weight species of 10,000-13,000.

E. coli enterotoxin vaccine for veterinary and human use

Endotoxin contaminant in meningococcus group A and group C polysaccharide is removed by means of a phosphate containing adsorbent.

Growing community of inventors

Scotch Plains, NJ, United States of America

Guadalupe A Limjuco